GROUNDBREAKING STUDY LAUNCHES

"Intermountain launches groundbreaking study using the PreTRM test to prevent preterm birth." Read more here

DOCTORS SPEAK OUT

"Women want good information. If a test predicts that they might have a preterm birth, they want to know."

PROTEOMIC INNOVATION

PreTRM Test Featured in Top-Tiered Scientific Journal as Example of Proteomic Test That Advances Patient Care. Read More

DOCTORS SPEAK OUT

"The value of the PreTRM test cannot be overestimated. We continue to deal with the vast majority of women who eventually go into preterm labor and deliver early with having absolutely no identifiable risk factors." Watch Dr. Shulman's video here

PROTEOMIC INNOVATION

“We developed a novel blood test to PREDICT, at an EARLY point in pregnancy, a woman’s individual risk of having a premature baby. We aim to achieve our vision of improving the health of newborns by enabling earlier, effective interventions that make a difference.” Dr. Greg Critchfield, CEO

DOCTORS SPEAK OUT

"With 1 in 10 women in the United States delivering prematurely, I believe every woman is an excellent candidate for the PreTRM test." Watch Dr. Mandel's video here

News

NEW SCIENTIFIC PUBLICATION SHOWS SERA PROGNOSTICS IS LEADER IN ASSESSING PRETERM BIRTH RISK

Nov 18, 2019 – Sera announced that a key scientific publication, “Effects of Selective Exclusion of Patients on Preterm Birth Test Performance,” authenticates Sera as the leading authority in using biomarkers to assess preterm birth risk. Read More >

SERA PROGNOSTICS RAISES $36 MILLION SERIES D FINANCING LED BY BLUE OX HEALTHCARE PARTNERS

Nov. 13, 2019 – Sera announced it has raised $36 million in Series D financing led by Blue Ox Healthcare Partners, an investment firm providing growth capital to healthcare companies targeting individuality and value-based care. Read More >

Sera Prognostics to Present at the 31st Annual Piper Jaffray Healthcare Conference

Nov. 1, 2019 -- Sera Prognostics will be presenting at the upcoming Piper Jaffray Healthcare Conference at the Lotte New York Palace in New York City on Thursday, December 5th at 12:30 p.m. ET. Read More >

Awards

Our Goals

Providing An Individualized Risk Assessment to Predict and Manage premature birth, preeclampsia, and other Pregnancy Complications

Sera Prognostics is focused on improving maternal and infant health by developing simple blood tests to predict the risks of pregnancy complications. Our initial focus is on one of the most serious pregnancy complications—preterm birth—which affects 9.6% of pregnancies in the U.S. alone.

Early and accurate prediction of risk for pregnancy complications may help pregnant women and their doctors take action and make a difference by putting early interventions in place. Learn about the PreTRM® Test for Risk Management.